Medicare Opens Weight-Loss Drug Access at $50 Monthly Copay

Medicare began covering three GLP-1 weight-loss drugs—Wegovy, Zepbound, and Foundayo—on July 1, 2026, at a fixed $50 monthly copay for eligible Part D enrollees. The program runs through December 2027, operating outside standard Part D formularies. This sidesteps typical specialty-drug cost-sharing; Wegovy's list price exceeds $1,000 monthly. CMS is treating the 18-month window as an evidence-gathering exercise before deciding whether to make coverage permanent.